These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 3818146)

  • 1. Plasma concentrations of ketanserin in chronic hemodialysed patients.
    Zazgornik J; Scholz N; Kuska J; Minar E
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):674-6. PubMed ID: 3818146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of propranolol on the steady-state plasma levels of ketanserin.
    Trenk D; Lühr A; Radkow N; Jähnchen E
    Arzneimittelforschung; 1985; 35(8):1286-8. PubMed ID: 2934070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Kinetics of metipranolol in patients with chronic kidney failure and during hemodialysis].
    Motán J; Mayer O; Spanĕl M
    Vnitr Lek; 1991 Mar; 37(3):285-92. PubMed ID: 1674391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketanserin pharmacokinetics in patients with renal failure.
    Barendregt JN; Van Peer A; Van Der Hoeven JG; Van Oene JC; Tjandra YI
    Br J Clin Pharmacol; 1990 Jun; 29(6):715-23. PubMed ID: 2378791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of astemizole in patients with terminal renal insufficiency, before, during and after hemodialysis.
    Zazgornik J; Scholz N; Heykants J; Vanden Bussche G
    Int J Clin Pharmacol Ther Toxicol; 1986 May; 24(5):246-8. PubMed ID: 2874116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction.
    Odar-Cederlöf I; Bjellerup P; Williams A; Blagg CR; Twardowski Z; Ting G; Kjellstrand CM
    Hemodial Int; 2006 Oct; 10(4):394-8. PubMed ID: 17014518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of transdermal clonidine in chronic hemodialysis patients.
    Rosansky SJ; Johnson KL; McConnell J
    Clin Nephrol; 1993 Jan; 39(1):32-6. PubMed ID: 8428405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
    Migliacci R; Falcinelli F; Imperiali P; Floridi A; Nenci GG; Gresele P
    Ital Heart J; 2004 May; 5(5):371-7. PubMed ID: 15185901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin elimination and hemostasis in hemodialysis.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of serum gentamicin concentrations in patients undergoing hemodialysis.
    Goetz DR; Pancorbo S; Hoag S; Bloom P
    Am J Hosp Pharm; 1980 Aug; 37(8):1077-83. PubMed ID: 7405935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Control of arterial hypertension by means of a regimen of hemodialysis on alternate days (HDAA or EODD: "Every Other Day Dialysis") versus 2 conventional regiments of 4 and 5 hours per session 3 times a week with 72 hours without sessions during the weekends].
    Lozano A; Benavides B; Quirós P; Jiménez-Moreno J; Figueroa E; Fernández-Marchena D; García-Pérez MA; Fernández-Ruiz E
    Nefrologia; 2006; 26(6):695-702. PubMed ID: 17227247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of moxalactam in anuric children and during hemodialysis.
    Kaplan SL; Berry PL; Mason EO; Kramer WG
    Pediatr Pharmacol (New York); 1983; 3(1):29-36. PubMed ID: 6646877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days--a randomized crossover trial between benidipine and nifedipine CR.
    Kojima M; Taniguchi M; Sato K; Ueda R; Dohi Y
    Nephron Clin Pract; 2004; 97(2):c49-53. PubMed ID: 15218330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sympathetic and plasma renin activity on hemodialysis hypertension.
    Grekas D; Kalevrosoglou I; Karamouzis M; Geropoulou E; Kabouris H; Tourkantonis A
    Clin Nephrol; 2001 Feb; 55(2):115-20. PubMed ID: 11269674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.